Print

Orchid Chemicals & Pharmaceuticals Ltd.
Unaudited Financial Results for Nine months ended December 31, 2005
           
(Rs.Lakhs)
S.No Particulars
Three months ended
December 31, 2005
(Unaudited)
Three months ended
December 31, 2004
(Unaudited)
Nine months ended
December 31, 2005
(Unaudited)
Nine months ended
December 31, 2004
(Unaudited)
Year ended March 31, 2005
(Audited)
1
 Sales and Operating Income
23760.49
17225.78
64717.80
50989.47
68929.44
2
 Other Income
49.86
93.02
205.03
192.88
82.24
3
 Total Expenditure
16834.78
13095.19
45873.60
39024.29
52700.71
a) Decrease/(Increase) in Stock in trade
(534.78)
(3538.13)
(4008.31)
(4362.80)
(9837.95)
b) Consumption of raw materials
9828.10
10675.07
29705.16
26970.13
39400.50
c) Staff Cost
1796.65
1549.75
4755.06
4096.85
5438.09
d) Other Expenditure
5744.81
4408.50
15421.69
12320.11
17700.07
4
Profit before Interest, Depreciation & Tax (1+2-3)
6975.57
4223.61
19049.23
12158.06
16310.97
5
 Interest and Finance Charges
2214.86
1792.11
6697.49
5372.57
7231.00
6
 Depreciation
1865.32
1556.39
5690.18
4635.50
6189.20
7
 Profit before tax (4-5-6)
2895.39
875.11
6661.56
2149.99
2890.77
8
 Provision for Taxation
      Current Tax
(46.00)
37.80
-
137.77
194.60
      Deferred Tax
-
261.13
180.00
570.81
(404.93)
      Fringe Benefit Tax
45.00
-
130.00
-
-
9
 Net Profit (7-8)
2896.39
576.18
6351.56
1441.41
3101.10
10
 Paid- up Equity Share Capital (Face value of Rs. 10 each)
6150.55
3238.19
6150.55
3238.19
3413.19
11
 Reserves excluding Revaluation Reserves
43714.20
12
 Basic Earnings per Share (Rs.)
4.71*
1.19**
10.33*
2.97**
6.36**
13 Diluted Earnings per Share (Rs.)
4.32*
1.14**
9.46*
2.86**
6.15**
             
* EPS is for the period (not annualised) after providing for taxes.
** EPS for earlier periods adjusted for the bonus issue.
 
  • The above financial results were taken on record by the Board of Directors at its meeting held on Thursday, January 19, 2006.
  • The Allotment Committee of the Board have allotted :
    - 105,000 equity shares to Promoter / Promoter Group on October 13, 2005 on conversion of warrants.
    - 8,650,000 Global Depository Receipts (GDRs) at a rate of US$ 4.34 (equivalent to Rs. 195.04 per share) and US$ 37,500,000 Zero Coupon Foreign Currency Convertible Bonds on November 02, 2005.
    - US$ 5,000,000 Zero Coupon Foreign Currency Convertible Bonds on November 14, 2005.
    - 600,000 GDRs at a rate of US$ 4.34 (equivalent to Rs. 195.04 per share) on November 29, 2005.
    - 19,649 shares to employees under ORCHID-ESOP 1999 Scheme, on December 23, 2005.
  • Consequent to the issue of bonus shares, the Board at its meeting held on October 13, 2005, adjusted the prices/ number of options/ shares in respect of unexercised Employee Stock Options and unconverted warrants.
  • The Company's increasing level of exports to regulated markets is in the form of finished dosage forms (formulations) which utilised the Company's active pharmaceutical ingredients (bulk drugs). In view of the integration of bulk actives and formulation business segments, the Company considers the business as one integrated business of "Pharmaceutical products" and hence no seperate segmental reporting is provided.
  • The above accounts have been subjected to limited review by the Statutory auditors.
  • Figures for the previous periods have been regrouped wherever necessary.
  • The Company received 15 complaints during the quarter ended December 31, 2005 from the shareholders, all the complaints have been resolved and no complaints were pending as on December 31, 2005.

Place : Chennai
Date : January 19, 2006

For and on behalf of the Board

K.Raghavendra Rao
Managing Director